Published in Biochem Pharmacol on April 15, 1992
Nrf1 and Nrf2 positively and c-Fos and Fra1 negatively regulate the human antioxidant response element-mediated expression of NAD(P)H:quinone oxidoreductase1 gene. Proc Natl Acad Sci U S A (1996) 5.15
Professor Tom Connors and the development of novel cancer therapies by the Phase I/II Clinical Trials Committee of Cancer Research UK. Br J Cancer (2003) 1.46
High throughput genotyping for the detection of a single nucleotide polymorphism in NAD(P)H quinone oxidoreductase (DT diaphorase) using TaqMan probes. Mol Pathol (1999) 1.35
Ethnic variation in the prevalence of a common NAD(P)H quinone oxidoreductase polymorphism and its implications for anti-cancer chemotherapy. Br J Cancer (1997) 1.32
Presence of a heterozygous substitution and its relationship to DT-diaphorase activity. Br J Cancer (1995) 1.28
Oleanolic acid activates Nrf2 and protects from acetaminophen hepatotoxicity via Nrf2-dependent and Nrf2-independent processes. Biochem Pharmacol (2009) 1.21
DT-diaphorase and cytochrome B5 reductase in human lung and breast tumours. Br J Cancer (1997) 1.12
DT-diaphorase protects cells from the hypoxic cytotoxicity of indoloquinone EO9. Br J Cancer (1994) 1.00
DT-diaphorase activity in normal and neoplastic human tissues; an indicator for sensitivity to bioreductive agents? Br J Cancer (1995) 0.95
Metabolism of the bioreductive cytotoxin SR 4233 by tumour cells: enzymatic studies. Br J Cancer (1993) 0.94
EO9: relationship between DT-diaphorase levels and response in vitro and in vivo. Br J Cancer (1995) 0.93
Disruption of NAD(P)H:quinone oxidoreductase 1 gene in mice leads to radiation-induced myeloproliferative disease. Cancer Res (2008) 0.90
Substrate specificity of an aflatoxin-metabolizing aldehyde reductase. Biochem J (1995) 0.90
Sulforaphane protects immature hippocampal neurons against death caused by exposure to hemin or to oxygen and glucose deprivation. J Neurosci Res (2010) 0.90
Higher activity of polymorphic NAD(P)H:quinone oxidoreductase in liver cytosols from blacks compared to whites. Toxicol Lett (2006) 0.89
Sulforaphane protects Microcystin-LR-induced toxicity through activation of the Nrf2-mediated defensive response. Toxicol Appl Pharmacol (2010) 0.89
Dietary induction of NQO1 increases the antitumour activity of mitomycin C in human colon tumours in vivo. Br J Cancer (2004) 0.87
Enhanced cytotoxicity of mitomycin C in human tumour cells with inducers of DT-diaphorase. Br J Cancer (1999) 0.85
Induction of DT-diaphorase by 1,2-dithiole-3-thiones in human tumour and normal cells and effect on anti-tumour activity of bioreductive agents. Br J Cancer (1998) 0.83
NQO1 C609T polymorphism correlated to colon cancer risk in farmers from western region of Inner Mongolia. Chin J Cancer Res (2012) 0.82
A unique cytosolic activity related but distinct from NQO1 catalyses metabolic activation of mitomycin C. Br J Cancer (2000) 0.81
Expression of human NAD(P)H: quinone oxidoreductase (DT-diaphorase) in Chinese hamster ovary cells: effect on the toxicity of antitumor quinones. Mol Pharmacol (1996) 0.80
Induction of DT-diaphorase by 1,2-dithiole-3-thione and increase of antitumour activity of bioreductive agents. Br J Cancer Suppl (1996) 0.80
Nuclear matrix protein (NRP/B) modulates the nuclear factor (Erythroid-derived 2)-related 2 (NRF2)-dependent oxidative stress response. J Biol Chem (2010) 0.79
One- and two-electron reduction of 2-methyl-1,4-naphthoquinone bioreductive alkylating agents: kinetic studies, free-radical production, thiol oxidation and DNA-strand-break formation. Biochem J (1994) 0.79
Overview of Nrf2 as Therapeutic Target in Epilepsy. Int J Mol Sci (2015) 0.78
A Model for NAD(P)H:Quinoneoxidoreductase 1 (NQO1) Targeted Individualized Cancer Chemotherapy. Drug Target Insights (2009) 0.77
Enhancement of radiation effect using beta-lapachone and underlying mechanism. Radiat Oncol J (2013) 0.76
Copper diethyldithiocarbamate as an activator of Nrf2 in cultured vascular endothelial cells. J Biol Inorg Chem (2016) 0.76
Cytotoxic mechanisms of anti-tumour quinones in parental and resistant lymphoblasts. Br J Cancer Suppl (1996) 0.75
Advanced glycation end products influence oral cancer cell survival via Bcl-xl and Nrf-2 regulation in vitro. Oncol Lett (2017) 0.75
Cyclophosphamides as hypoxia-activated diffusible cytotoxins: a theoretical study. J Comput Aided Mol Des (2000) 0.75
DT-Diaphorase expression and tumor cell sensitivity to 17-allylamino, 17-demethoxygeldanamycin, an inhibitor of heat shock protein 90. J Natl Cancer Inst (1999) 3.07
The assessment of antiangiogenic and antivascular therapies in early-stage clinical trials using magnetic resonance imaging: issues and recommendations. Br J Cancer (2005) 2.85
Reductase enzyme expression across the National Cancer Institute Tumor cell line panel: correlation with sensitivity to mitomycin C and EO9. J Natl Cancer Inst (1996) 2.20
Estimation of the hypoxic cell-sensitiser misonidazole and its O-demethylated metabolite in biological materials by reversed-phase high-performance liquid chromatography. J Chromatogr (1978) 2.08
Inhibition of signal transduction by the Hsp90 inhibitor 17-allylamino-17-demethoxygeldanamycin results in cytostasis and apoptosis. Cancer Res (2001) 1.86
Direct measurement of pO2 distribution and bioreductive enzymes in human malignant brain tumors. Int J Radiat Oncol Biol Phys (1994) 1.84
Anticancer agents targeting signaling molecules and cancer cell environment: challenges for drug development? J Natl Cancer Inst (1999) 1.70
A phase I trial of the selective oral cyclin-dependent kinase inhibitor seliciclib (CYC202; R-Roscovitine), administered twice daily for 7 days every 21 days. Br J Cancer (2006) 1.66
Partition coefficient as a guide to the development of radiosensitizers which are less toxic than misonidazole. Radiat Res (1980) 1.64
Personalized cancer medicine: molecular diagnostics, predictive biomarkers, and drug resistance. Clin Pharmacol Ther (2012) 1.60
9-Alkyl, morpholinyl anthracyclines in the circumvention of multidrug resistance. Eur J Cancer (1990) 1.59
Establishment and characterisation of cell lines from patients with lung cancer (predominantly small cell carcinoma). Br J Cancer (1985) 1.52
Progress in the preclinical discovery and clinical development of class I and dual class I/IV phosphoinositide 3-kinase (PI3K) inhibitors. Curr Med Chem (2011) 1.44
Pharmacokinetic considerations in testing hypoxic cell radiosensitizers in mouse tumours. Br J Cancer (1979) 1.42
Gene expression profiling of human colon cancer cells following inhibition of signal transduction by 17-allylamino-17-demethoxygeldanamycin, an inhibitor of the hsp90 molecular chaperone. Oncogene (2000) 1.34
Examination by laser scanning confocal fluorescence imaging microscopy of the subcellular localisation of anthracyclines in parent and multidrug resistant cell lines. Br J Cancer (1993) 1.34
Phenytoin shortens the half-life of the hypoxic cell radiosensitizer misonidazole in man: implications for possible reduced toxicity. Br J Cancer (1980) 1.33
Modification of CCNU pharmacokinetics by misonidazole--a major mechanism of chemosensitization in mice. Br J Cancer (1983) 1.33
The role of NAD(P)H: quinone reductase (EC 1.6.99.2, DT-diaphorase) in the reductive bioactivation of the novel indoloquinone antitumor agent EO9. Cancer Commun (1991) 1.32
Monitoring salivary misonidazole in man: a possible alternative to plasma monitoring. Br J Cancer (1978) 1.29
A chemical inhibitor of PPM1D that selectively kills cells overexpressing PPM1D. Oncogene (2007) 1.27
Assessment of antiangiogenic and antivascular therapeutics using MRI: recommendations for appropriate methodology for clinical trials. Br J Radiol (2003) 1.27
Gene expression microarray analysis in cancer biology, pharmacology, and drug development: progress and potential. Biochem Pharmacol (2001) 1.24
Silencing the cochaperone CDC37 destabilizes kinase clients and sensitizes cancer cells to HSP90 inhibitors. Oncogene (2008) 1.24
Effects of pretreatment with phenobarbitone and phenytoin on the pharmacokinetics and toxicity of phenytoin on the pharmacokinetics and toxicity of misonidazole in mice. Br J Cancer (1979) 1.23
Hsp90 inhibitors in the clinic. Handb Exp Pharmacol (2006) 1.21
Targeting heat shock protein 72 enhances Hsp90 inhibitor-induced apoptosis in myeloma. Leukemia (2010) 1.19
Discovering novel chemotherapeutic drugs for the third millennium. Eur J Cancer (1999) 1.17
Selective FLT3 inhibition of FLT3-ITD+ acute myeloid leukaemia resulting in secondary D835Y mutation: a model for emerging clinical resistance patterns. Leukemia (2012) 1.16
Structure-pharmacokinetic relationships for misonidazole analogues in mice. Cancer Chemother Pharmacol (1981) 1.14
Molecular enzymology of the reductive bioactivation of hypoxic cell cytotoxins. Int J Radiat Oncol Biol Phys (1989) 1.13
An investigation of the possibility of chemosensitization by clinically achievable concentrations of misonidazole. Br J Cancer (1983) 1.11
Clinical studies with misonidazole. Br J Cancer Suppl (1978) 1.10
Pharmacokinetics of hypoxic cell radiosensitizers: a review. Cancer Clin Trials (1980) 1.09
Pharmacokinetic and tumour-penetration properties of the hypoxic cell radiosensitizer desmethylmisonidazole (Ro 05-Ro-9963) in dogs. Br J Cancer (1980) 1.08
Preclinical pharmacokinetics and metabolism of a novel prototype DNA-PK inhibitor NU7026. Br J Cancer (2005) 1.07
Pharmacokinetics of the hypoxic cell cytotoxic agent tirapazamine and its major bioreductive metabolites in mice and humans: retrospective analysis of a pharmacokinetically guided dose-escalation strategy in a phase I trial. Cancer Chemother Pharmacol (1997) 1.07
A Phase I study of the angiogenesis inhibitor SU5416 (semaxanib) in solid tumours, incorporating dynamic contrast MR pharmacodynamic end points. Br J Cancer (2005) 1.07
Is body composition an important variable in the pharmacokinetics of anticancer drugs? A review and suggestions for further research. Cancer Chemother Pharmacol (1994) 1.06
Drug metabolism and chemosensitization. Nitroimidazoles as inhibitors of drug metabolism. Biochem Pharmacol (1983) 1.06
From darkness to light with biomarkers in early clinical trials of cancer drugs. Clin Pharmacol Ther (2009) 1.06
Retention of activity by selected anthracyclines in a multidrug resistant human large cell lung carcinoma line without P-glycoprotein hyperexpression. Br J Cancer (1991) 1.06
Unusually marked hypoxic sensitization to indoloquinone EO9 and mitomycin C in a human colon-tumour cell line that lacks DT-diaphorase activity. Int J Cancer (1994) 1.04
Dose-dependence and related studies on the pharmacokinetics of misonidazole and desmethylmisonidazole in mice. Cancer Chemother Pharmacol (1980) 1.02
Measurement of tumor oxygenation: in vivo comparison of a luminescence fiber-optic sensor and a polarographic electrode in the p22 tumor. Radiat Res (2001) 1.02
Enhancement by electron-affinic agents of the therapeutic effects of cytotoxic agents against the KHT tumor: structure-activity relationships. Int J Radiat Oncol Biol Phys (1982) 1.01
DT-diaphorase protects cells from the hypoxic cytotoxicity of indoloquinone EO9. Br J Cancer (1994) 1.00
Preclinical antitumor activity and pharmacodynamic studies with the farnesyl protein transferase inhibitor R115777 in human breast cancer. Clin Cancer Res (2001) 0.99
Clinical anticancer drug development: targeting the cyclin-dependent kinases. Br J Cancer (2005) 0.99
Enzymology of the reductive bioactivation of SR 4233. A novel benzotriazine di-N-oxide hypoxic cell cytotoxin. Biochem Pharmacol (1990) 0.99
Demonstration of tumor-selective retention of fluorinated nitroimidazole probes by 19F magnetic resonance spectroscopy in vivo. Int J Radiat Oncol Biol Phys (1989) 0.99
Structure/activity relationships for the enhancement by electron-affinic drugs of the anti-tumour effect of CCNU. Br J Cancer (1982) 0.98
The role of cytochrome P450 and cytochrome P450 reductase in the reductive bioactivation of the novel benzotriazine di-N-oxide hypoxic cytotoxin 3-amino-1,2,4-benzotriazine-1,4-dioxide (SR 4233, WIN 59075) by mouse liver. Biochem Pharmacol (1992) 0.98
A fluorescence polarization assay for inhibitors of Hsp90. Anal Biochem (2006) 0.96
Catalytic properties of NAD(P)H:quinone acceptor oxidoreductase: study involving mouse, rat, human, and mouse-rat chimeric enzymes. Mol Pharmacol (1995) 0.96
Effect of misonidazole or metronidazole pretreatment on the response of the RIF-1 mouse sarcoma to melphalan, cyclophosphamide, chlorambucil and CCNU. Br J Cancer (1982) 0.96
Normalisation of anti-cancer drug dosage using body weight and surface area: is it worthwhile? A review of theoretical and practical considerations. Cancer Chemother Pharmacol (1993) 0.95
Identification of anthracyclines and related agents that retain preferential activity over adriamycin in multidrug-resistant cell lines, and further resistance modification by verapamil and cyclosporin A. Cancer Chemother Pharmacol (1989) 0.94
Phospholipid antitumor agents. Med Res Rev (1995) 0.93
Preclinical pharmacokinetics of benznidazole. Br J Cancer (1984) 0.93
Relative importance of DT-diaphorase and hypoxia in the bioactivation of EO9 by human lung tumor cell lines. Int J Radiat Oncol Biol Phys (1994) 0.93
Initial characterization of the major mouse cytochrome P450 enzymes involved in the reductive metabolism of the hypoxic cytotoxin 3-amino-1,2,4-benzotriazine-1,4-di-N-oxide (tirapazamine, SR 4233, WIN 59075). Biochem Pharmacol (1993) 0.92
Improved cellular accumulation is characteristic of anthracyclines which retain high activity in multidrug resistant cell lines, alone or in combination with verapamil or cyclosporin A. Biochem Pharmacol (1989) 0.92
Nitroimidazole bioreductive metabolism. Quantitation and characterisation of mouse tissue benznidazole nitroreductases in vivo and in vitro. Biochem Pharmacol (1987) 0.92
Reduction of 3-amino-1,2,4-benzotriazine-1,4-di-N-oxide (tirapazamine, WIN 59075, SR 4233) to a DNA-damaging species: a direct role for NADPH:cytochrome P450 oxidoreductase. Carcinogenesis (1994) 0.91
Decreased NADPH:cytochrome P-450 reductase activity and impaired drug activation in a mammalian cell line resistant to mitomycin C under aerobic but not hypoxic conditions. Cancer Res (1990) 0.91
High dose BCNU chemotherapy with autologous bone marrow transplantation and full dose radiotherapy for grade IV astrocytoma. Br J Cancer (1988) 0.91
A flow cytofluorimetric method for measuring enzyme reaction kinetics in intact cells. FEBS Lett (1977) 0.90
The role of functional and molecular imaging in cancer drug discovery and development. Br J Radiol (2003) 0.90
DT-diaphorase activity correlates with sensitivity to the indoloquinone EO9 in mouse and human colon carcinomas. Eur J Cancer (1992) 0.90
The role of human and rodent DT-diaphorase in the reductive metabolism of hypoxic cell cytotoxins. Int J Radiat Oncol Biol Phys (1992) 0.89
Drug interactions with misonidazole: effects of dexamethasone and its derivatives on the pharmacokinetics and toxicity of misonidazole in mice. Biochem Pharmacol (1980) 0.89
Infusional anthracyclines: is slower better? If so, why? Ann Oncol (1992) 0.89
The pharmacokinetics and tumor and neural tissue penetrating properties of SR-2508 and SR-2555 in the dog--hydrophilic radiosensitizers potentially less toxic than misonidazole. Radiat Res (1980) 0.87
Use of radiolabelled choline as a pharmacodynamic marker for the signal transduction inhibitor geldanamycin. Br J Cancer (2002) 0.87
The pharmacokinetics of misonidazole in the dog. Eur J Cancer (1979) 0.87
Pharmacokinetics and metabolism of the mixed-function hypoxic cell sensitizer prototype RSU 1069 in mice. Cancer Chemother Pharmacol (1988) 0.87
Pharmacology of the mixed-function radio- and chemosensitizers CB 1954 and RSU 1069. Int J Radiat Oncol Biol Phys (1984) 0.87
Pharmacokinetics and bioreductive metabolism of the novel benzotriazine di-N-oxide hypoxic cell cytotoxin tirapazamine (WIN 59075; SR 4233; NSC 130181) in mice. J Pharmacol Exp Ther (1993) 0.87
Measuring changes in human tumour vasculature in response to therapy using functional imaging techniques. Br J Cancer (2001) 0.86
Evaluation of the cassette dosing approach for assessing the pharmacokinetics of geldanamycin analogues in mice. Cancer Chemother Pharmacol (2004) 0.86
In vivo evaluation of [18F]fluoroetanidazole as a new marker for imaging tumour hypoxia with positron emission tomography. Br J Cancer (2004) 0.86
The in vitro effects and cross-resistance patterns of some novel anthracyclines. Br J Cancer (1986) 0.86
A phase I study of the nitroimidazole hypoxia marker SR4554 using 19F magnetic resonance spectroscopy. Br J Cancer (2009) 0.86
In vitro selectivity, in vivo biodistribution and tumour uptake of annexin V radiolabelled with a positron emitting radioisotope. Br J Cancer (2003) 0.86
Acute tumour response to the MEK1/2 inhibitor selumetinib (AZD6244, ARRY-142886) evaluated by non-invasive diffusion-weighted MRI. Br J Cancer (2013) 0.86
Involvement of NADPH: cytochrome P450 reductase in the activation of indoloquinone EO9 to free radical and DNA damaging species. Biochem Pharmacol (2001) 0.85
High-throughput screening for identification of small molecule inhibitors of histone acetyltransferases using scintillating microplates (FlashPlate). Anal Biochem (2001) 0.85
Enzymology of the reduction of the potent benzotriazine-di-N-oxide hypoxic cell cytotoxin SR 4233 (WIN 59075) by NAD(P)H: (quinone acceptor) oxidoreductase (EC 1.6.99.2) purified from Walker 256 rat tumour cells. Biochem Pharmacol (1992) 0.85
A clinical phase I toxicity study of Ro 03-8799: plasma, urine, tumour and normal brain pharmacokinetics. Br J Radiol (1986) 0.85
Characterization of a human colorectal carcinoma cell line with acquired resistance to flavopiridol. Mol Pharmacol (2001) 0.85
The effects of alpha and gamma interferons on human lung cancer cells grown in vitro or as xenografts in nude mice. Br J Cancer (1985) 0.85
Establishment of an isogenic human colon tumor model for NQO1 gene expression: application to investigate the role of DT-diaphorase in bioreductive drug activation in vitro and in vivo. Mol Pharmacol (2000) 0.85
Polar fluorescein derivatives as improved substrate probes for flow cytoenzymological assay of cellular esterases. Mol Cell Probes (1988) 0.85
Bioreductive drugs into the next millennium. Anticancer Drug Des (1998) 0.85
Multiparametric analysis of cell membrane permeability by two colour flow cytometry with complementary fluorescent probes. Cytometry (1990) 0.84
A phase I study of the combination of benznidazole and CCNU in man. Int J Radiat Oncol Biol Phys (1984) 0.84
Chemosensitization by lipophilic nitroimidazoles. Br J Cancer (1983) 0.84
Development and validation of a sensitive solid-phase-extraction and high-performance liquid chromatography assay for the bioreductive agent tirapazamine and its major metabolites in mouse and human plasma for pharmacokinetically guided dose escalation. Cancer Chemother Pharmacol (1995) 0.84